Category: 3. Business

  • British Columbia introduces new extended leave for serious illness or injury under Employment Standards Act

    At a glance

    • The Government of British Columbia is proposing to expand job-protected leave entitlements.
    • Qualifying employees could receive up to 27 weeks’ leave within a 52-week period if they are unable to work due to a serious personal injury or illness.
    • If enacted, BC employers will have to update leave policies / practices to provide extended job-protected leave for serious illness or injury. 

    On October 20, 2025, the Government of British Columbia introduced Bill 30, the Employment Standards (Serious Illness or Injury Leave) Amendment Act, 2025. This Bill proposes to expand job-protected leave entitlements under the BC Employment Standards Act (ESA). 

    In its current form, Bill 30 would provide qualified employees up to 27 weeks of unpaid, job-protected leave within a 52-week period if they are unable to work due to a serious personal injury or illness. The proposed extended leave is intended to assist employees with long-term medical treatment and recovery, bringing BC’s employment standards protections in line with several other Canadian jurisdictions and the federal Employment Insurance Sickness Benefits program.

    Employees wishing to qualify for this leave would be required to present a certificate from a health practitioner setting out that the employee is unable to work due to a medical condition, as well as the start and end dates of the leave. This medical certificate requirement differs from short-term sick leave. The new rules under the ESA regarding short-term sick leave expressly prohibit BC employers from requiring proof of illness from employees, as we discussed in a previous post. These rules have received royal assent but are yet to come into force.

    The proposed extended leave must be taken in increments of at least one week. If the full 27 weeks of leave are not used within 52 weeks from the leave start date, the remaining entitlement may be resumed or extended within that same period, provided the medical requirements are met. 

    If an employee on the leave returns to work but becomes unable to continue working because of the same medical condition, the proposed amendments provide for additional leave without a new certificate, provided the 27 weeks of leave have not been exhausted within the 52-week period.  

    Takeaways for employers

    If enacted, Bill 30 will require BC employers to update their leave policies and practices to provide extended job-protected leave for serious illness or injury pursuant to the ESA. We encourage employers to begin reviewing policy language and ensuring HR teams are aware of the proposed changes. 

    Continue Reading

  • Ed Miliband says £1.1bn a year to be set aside for new offshore wind projects | Wind power

    Ed Miliband says £1.1bn a year to be set aside for new offshore wind projects | Wind power

    The energy secretary, Ed Miliband, has set aside £1.1bn a year for offshore wind power developers investing in new projects, in the latest funding round aimed at meeting the UK’s green electricity targets.

    The government’s energy department said today it had budgeted £900m to pay developers of fixed wind turbines at sea, with another £180m for floating platforms.

    Renewables provided about half of the UK’s electricity during 2024, with wind accounting for 30% of generation for the first time – overtaking gas power stations. Further huge investments in wind and solar would be necessary to meet the target of completely removing carbon emissions from British electricity supplies by 2030.

    Government sources have previously said ministers might consider abandoning the 2030 target – long seen as hugely ambitious by experts – if it were to add too much to household bills. The Labour government’s clean electricity target is opposed by the Conservative party and Reform, who say they would ditch net zero policies.

    A government source disputed that the 2030 target was in question, saying the initial budget for offshore wind showed “big backing by the Treasury”.

    Wind power developers, expected to include the energy companies SSE, RWE and ScottishPower, will be invited to bid to build offshore wind projects, which would be eligible to receive the new funds.

    In a change from previous years, the final budget could rise higher if ministers considered enough projects provided value for money – potentially surpassing the £1.1bn allocated to offshore wind last year. The contracts would also last 20 years, rather than 15, in order to try to attract lower prices.

    However, RenewableUK, an industry lobby group, said the budget would cover only about a quarter of the 20 gigawatts of projects that have planning permission and would be eligible. Ana Musat, the group’s executive director of policy, said: “The budget announced today will not maximise investment in new offshore windfarms.”

    Chris Stark, the civil servant who leads the UK’s clean power efforts under Miliband, said he expected the bids to exceed the funding allocated for fixed offshore wind. The government was prepared to “contract more offshore wind generation if we see value for money for the consumer”, he said in a social media post.

    Michael Shanks, minister of state for energy, said: “This auction is another step towards delivering the clean power this country needs to end our reliance on volatile global gas prices, ensuring our energy security and bringing down bills for good.

    “Our competitive new auction process will allow us to buy the right amount of clean power at the right price on behalf of the British people, so we can take back control of our energy.”

    skip past newsletter promotion

    The budget allocated by the government may not all be spent, but rather represents the “worst case” cost under the “contracts for difference” (CfD) scheme, which reduces the risk for developers investing in clean power generation.

    Under the scheme, the government sets a bar for electricity prices generated from the projects. If prices are below that bar, called a strike price, the government tops up the difference, while generators must pay back the government for any earnings above that price. The whole budget would be spent only if energy prices were to stay lower than expected for a sustained period of time.

    Jess Ralston, head of energy at the Energy and Climate Intelligence Unit, a thinktank, said: “Every bit of free wind and sun power that we harness means we need to buy less foreign gas from abroad, boosting our energy security.”

    Continue Reading

  • Correction to chromium alumino-thermic 99% min, in-whs Rotterdam price assessment, rationale on October 24

    Correction to chromium alumino-thermic 99% min, in-whs Rotterdam price assessment, rationale on October 24

    MB-CR-0001 Chromium alumino-thermic 99% min, in-whs Rotterdam, $/tonne was published in error at $8,800-9,200 per tonne. It has been corrected to $8,800-9,476 per tonne.

    Fastmarkets’ pricing database and the relevant rationale has been updated to reflect this change.

    This price is part of the Fastmarkets minor metals package.

    For more information or to provide feedback on this correction notice, or if you would like to provide price information by becoming a data submitter to this price assessment, please contact pricing@fastmarkets.com and minormetals@fastmarkets.com. Please add the subject heading “re: chromium alumino-thermic 99% min, in-whs Rotterdam.“

    Please indicate if comments are confidential. Fastmarkets will consider all comments received and will make comments not marked as confidential available upon request.

    To see all Fastmarkets pricing methodology and specification documents, go to the Fastmarkets methodology page.

    Continue Reading

  • Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

    Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

    Results from the phase 3 IMvigor011 trial (NCT04660344) evaluating adjuvant atezolizumab (Tecentriq) showed that circulating tumor DNA (ctDNA) testing could refine muscle-invasive bladder cancer (MIBC) management by guiding adjuvant immunotherapy decisions, although further research is needed to enhance treatment precision across disease stages and regimens, according to Joaquim Bellmunt, MD, PhD.

    In an interview with OncLive®, Bellmunt highlighted ways that ctDNA testing could augment bladder cancer treatment standards, the need for data from ongoing trials to determine the optimal use of ctDNA test results in various clinical scenarios, and the promise of ctDNA results for identifying patients likely to benefit from immunotherapy. He discussed the IMvigor011 trial results in more detail in another portion of the interview.

    Bellmunt is director of the Bladder Cancer Center and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

    OncLive: What do the IMvigor011 data indicate about the potential role for ctDNA in bladder cancer detection and management? What additional data are needed to help determine how to incorporate this information into clinical decision-making strategies?

    Bellmunt: [ctDNA analyses are] happening in [many] diseases. Sometimes we are lagging behind in how the [urothelial cancer treatment paradigm] is evolving. Nowadays, for example, since [IMvigor11] was designed in [2020], we have had several positive trials. We have had the phase 3 NIAGARA trial [NCT03732677], where patients [with MIBC] received neoadjuvant chemoimmunotherapy followed by surgery, and then adjuvant durvalumab [Imfinzi] for 8 cycles, independent of their pathological response after neoadjuvant chemoimmunotherapy.

    At the 2025 ESMO Congress, we also heard the outstanding results on the use [of pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv (Padcev)] in patients [with MIBC] who are unfit for platinum[-based chemotherapy]; [this regimen is] 3 cycles [of the combination] before surgery, and then after surgery, patients receive 6 additional cycles [of the combination] and then maintenance immunotherapy [with pembrolizumab alone]. This phase 3 KEYNOTE-905/EV-303 [trial (NCT03924895) regimen] is likely a new standard of care because for the first time, we have seen a survival benefit in patients receiving neoadjuvant enfortumab vedotin/pembrolizumab, followed by adjuvant [treatment with the combination, followed by pembrolizumab alone]. We have seen a [57.1% (95% CI, 49.3%-64.6%)] pathologic complete response [(pCR) rate with this regimen].1 Those are outstandingly good results never seen before.

    IMvigor011 Trial: Key Takeaways

    • Adjuvant atezolizumab significantly improved disease-free survival (DFS; HR, 0.64; 95% CI, 0.47-0.87; P = .0047) and overall survival (OS; HR, 0.59; 95% CI, 0.39-0.90; P = .0131) compared with placebo in patients with ctDNA-positive MIBC.
    • Patients who persistently tested ctDNA negative had a low risk of recurrence and death, with only 10.9% of patients experiencing a DFS event and 3.9% of patients experiencing an OS event in the no-treatment population after a median follow-up of 21.8 months from cystectomy.
    • Subgroup analysis for DFS revealed a particularly strong benefit with atezolizumab in patients with high PD-L1 status (HR, 0.33; 95% CI, 0.19-0.58) and those who tested ctDNA positive earlier following cystectomy (HR, 0.52; 95% CI, 0.36-0.74).

    The question is: How are we going to use ctDNA in other trials? The results of IMvigor011 [were] based on the decision to give adjuvant treatment in patients who were ctDNA positive. Is [ctDNA] going to be used in other settings? Those are questions that unless we get results from these ongoing or completed trials, we cannot start extrapolating.

    What [should we] do in patients who have a pCR? Do we need to give, for example, 8 cycles of adjuvant immunotherapy? Data from the breast cancer [field are] telling that, yes, despite the pCRs, still there is benefit [with additional immunotherapy]. However, if the patient’s getting a CR after neoadjuvant chemoimmunotherapy, maybe they will not be willing to receive adjuvant treatment.

    These are good questions. The paradigm is evolving, so [there will be] new treatment options for patients. We’ll see how [these new data are] going to [affect it] in the end.

    What are the next steps for the IMvigor011 investigation?

    [We presented] the initial results [at ESMO 2025].2 We are analyzing the cohort of patients with more granularity. For example, [we are investigating] how the ctDNA affects or correlates with staging before receiving neoadjuvant therapy or at the time of surgery; this might give us [more] prognostic data.

    We know that ctDNA is prognostic. Patients who have high ctDNA levels do worse than patients who are ctDNA negative. [However, there may be] correlations made in this trial, [such as] correlations between staging, response to prior treatment, and patient outcomes.

    How do the IMvigor011 results open the door for a new treatment paradigm for patients with bladder cancer who are positive for recurrence on a molecular level without evidence of disease progression or recurrence on imaging?

    [IMvigor011] formed the basis for other trials that are already ongoing. For example, we have the phase 2/3 MODERN trial [NCT05987241], where patients with [urothelial cancer with] ctDNA positivity are assigned to receive immunotherapy. That trial is asking an additional question: Can we optimize adjuvant therapy? For example, in the MODERN trial, patients who are ctDNA positive are randomly assigned to receive nivolumab [Opdivo] or nivolumab plus a LAG-3 inhibitor—another immunotherapy compound. This could potentially end up [showing that patients] can obtain further benefit if they are adding immunotherapy compounds to an immunotherapy [backbone] in patients who are ctDNA positive.

    [ctDNA analysis] is a dynamic test. In [the phase 3] IMvigor010 [trial (NCT02450331)], we only had baseline [testing for] determination of ctDNA [status]. [In IMvigor011], we had sequential checking of ctDNA for up to 1 year. In patients who are [ctDNA] negative after 1 year, the likelihood of recurrence was only [11.6% at 24 months without adjuvant treatment].

    References

    1. Vulsteke C, Kaimakliotis HZ, Danchaivijitr P, et al. Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: phase 3 KEYNOTE-905 study. Presented at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract LBA2.
    2. Powles T, Kann AG, Castellano D, et al. IMvigor011: a phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Presented at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract LBA8.

    Continue Reading

  • Clarification of methodology for Turkey domestic long steel assessments

    Clarification of methodology for Turkey domestic long steel assessments

    The assessments are for MB-STE-0784 steel reinforcing bar (rebar) domestic, exw Turkey and MB-STE-0785 steel wire rod (mesh quality) domestic, exw Turkey.

    Previously, both assessments stated that an 18% value-added tax (VAT) was included in the assessed price. Fastmarkets wishes to clarify the specifications to show the correct figure, which is 20%, as dictated by Turkish tax rules.

    Turkey changed its VAT rate from 18% to 20% in July 2023. The specifications of affected prices were not updated at the time, but prices have been assessed in line with the VAT change.

    The clarified specifications are:

    MB-STE-0784 Steel reinforcing bar (rebar) domestic, exw Turkey, lira/tonne
    Quality: Diameter 12-32mm
    Quantity: Minimum 100 tonnes
    Location: Ex-works
    Timing: Up to 6 weeks
    Unit: TRY/tonne including 20% VAT
    Payment terms: LC, Bank transfer, cash upon order, deferred payment
    Publication: Weekly. Thursday, 2-3pm London time

    MB-STE-0785 Steel wire rod (mesh quality) domestic, exw Turkey, lira/tonne
    Quality: Standard diameter 5.5-32mm
    Quantity: Standard 100 tonnes
    Location: Ex-works
    Timing: Prompt to 6 weeks
    Unit: TRY/tonne including 20% VAT
    Payment terms: LC, Bank transfer, cash upon order, deferred payment
    Publication: Weekly. Thursday, 2-3pm London time

    You can find the updated methodology for ferrous products here: https://www.fastmarkets.com/methodology/.

    To see all Fastmarkets pricing methodology and specification documents, go to the Fastmarkets methodology page.

    Continue Reading

  • Eastern Airways on brink of collapse putting with jobs at risk

    Eastern Airways on brink of collapse putting with jobs at risk

    UK regional airline Eastern Airways is on the brink of collapse, putting hundreds of jobs at risk.

    On Monday it filed a notice of intention to appoint an administrator, and several regional flights were cancelled including between between Teesside and Aberdeen.

    Eastern Airways operates across the UK, Ireland and Europe, and has run services supported by the Scottish government for people in the northernmost point of mainland UK.

    Eastern Airways and The UK Civil Aviation Authority (CAA) have been approached for comment.

    A notice to appoint administrators is a formal step that gives the business up to 10 days of legal protection from creditors while it explores rescue options, restructures, or prepares for insolvency proceedings.

    Airport flight departure boards showed Eastern Airways flights had been cancelled, including a 0700 flight from Newquay to London Gatwick, 1815 flight from Teesside to Aberdeen, 1430 from Aberdeen to Wick and 1645 from Aberdeen to Teesside.

    Eastern Airways is one of the UK’s last remaining regional airlines.

    It has been an operator in the oil and gas industry, flying between UK cities with a significant presence in the sector such as Aberdeen, Humberside, Teesside and Wick.

    The airline faced financial challenges following the pandemic, due in part to falling passenger numbers.

    Launched in 1997, Eastern Airways is based at Humberside Airport in North Lincolnshire. The airline also operates out of East Midlands, Jersey, Manchester, Newcastle, Newquay and Southampton, as well as Esbjerg in Denmark.

    It has run a crucial weekday service between Wick John O’Groats Airport and Aberdeen, which is seen as vital for people living in the most northerly point on mainland UK, which was supported by a Public Service Obligation (PSO) by the Scottish Government.

    Eastern Airways initially built up its network of scheduled services around the North Sea offshore industry with flights up the east coast of England to Aberdeen.

    Continue Reading

  • How John Williamson transformed the LME

    How John Williamson transformed the LME

    Key takeaways:

    • LME’s transformation under John Williamson: From navigating the 2022 nickel crisis to modernizing systems and governance, Williamson has steered the LME toward renewed trust and market confidence
    • Driving modernization and sustainability: Williamson’s tenure emphasizes electronic pricing, enhanced transparency, and sustainability initiatives like the Dubai-based CPAL for greener metals
    • Strengthened global partnerships: Closer ties with HKEX have fueled expansion, governance reforms, and strategic growth, positioning the LME for a dynamic future

    The nickel crisis of 2022 had tested its systems, its governance and its reputation. Three years later, Williamson says that the LME is “no longer the ugly duckling” – a reference to the fable he uses to describe its transformation – but is now an exchange regaining confidence, focus and trust.

    “It brings you back to the story of the ugly duckling,” Williamson told Fastmarkets in an interview on Friday October 24. “When I arrived as chairman, things were rather bleak, and I sensed pretty quickly that we had very good people at the LME and that, like the duckling, with the right support, encouragement and sense of belief, great things could be achieved.”

    Since then, he has presided over an intense period of reform: rebuilding governance, strengthening market surveillance and modernizing systems, all while pushing forward with new initiatives on sustainability and digital trading. “If my legacy was that I had at least helped that duckling gain some more confidence, I’d be happy,” he said.

    Rebuilding after crisis

    Williamson did not seek the chairmanship. He was a long-serving board member of Hong Kong Exchanges & Clearing (HKEX) – the Hong Kong-based owner of the LME – and was invited to join the LME board in 2021 soon after retiring from HKEX. When his predecessor stepped down after the nickel market turmoil, he was asked to lead the exchange through its most testing period in decades.

    In his view, the nickel crisis proved to be a turning point.

    “Much has been learned from the nickel event, not least in terms of our surveillance of what’s happening in the broader market, and the need for us to have access to as much information as possible, on both the over-the-counter [OTC] and exchange business,” he said. “I think we’re in a better place there.”

    The crisis, he said, helped to drive overdue change within the industry, with members becoming more receptive to reforms once they saw the need for greater transparency and oversight. The exchange introduced daily price limits, enhanced data collection on OTC positions, and other measures that helped to facilitate a more comprehensive and proactive approach to risk monitoring.

    “If we’re looking for evidence that the changes we’ve been making are beneficial to the market, we can already see some of that,” he said.

    Modernizing the market

    Williamson’s tenure has been defined by a push to modernize – from electronic pricing and enhanced liquidity programs to IT system upgrades and new product development. It is a strategy that he defines as “evolution, not revolution.”

    “It’s about ensuring that the LME remains the premier venue for trading industrial metals,” he said. “We must continue to nurture and build on the trust that exists in the LME in terms of participants’ desire to use it for reference pricing, and we also must move with the times in terms of being efficient and effective in the way we operate.”

    The exchange has rolled out electronic closing prices and market structure reforms intended to increase transparency and attract a wider pool of participants.

    “We understand the concerns that some market participants have,” he said. “But if I look, for example, at the changes we made to the closing prices, and making those electronic, what you see is a fairly significant increase in volume. And even those who were opposed to us taking those steps have by and large come round to them.”

    Dubai and the CPAL

    Beyond technology, Williamson is also driving a longer-term strategy concerning sustainability and global reach. One of his key priorities is the creation of the Commodity Pricing and Analysis Ltd (CPAL) operation in Dubai, a major step in developing a premium market for greener metal.

    “Another important area, which is more business development than reform, is to continue to pursue the sustainability agenda. Setting up the CPAL operation will be very helpful on that part of the journey,” he said, noting it will operate as an independent pricing administrator.

    Williamson sees the project as part of the LME’s role to help the industry to recognize and reward lower-carbon production.

    “If you make the criteria too demanding, there’ll be no trading,” he said. “So we probably have to start at a reasonable point and then – over time, when we get the right engagement, the right volume – ratchet-up the criteria. Because if the whole idea is to encourage more sustainable green mining, you want to raise the bar over time, in line with broader expectations and policy measures.”

    The initiative mirrors the earlier success of LMEpassport, a traceability tool that once faced skepticism but is now widely used. “When we started to look at LMEpassport, there were a lot of detractors saying it was not really our business to go down that path. But thank goodness we did,” he said.

    HKEX partnership

    According to Williamson, the LME’s relationship with parent company HKEX – once perceived as distant – has become closer and, strategically, more aligned.

    “The engagement with Hong Kong is stronger, not in a micro-managing way, but the business development opportunities are better understood,” he said. “We have, I’d say, an even stronger relationship with Hong Kong. And how does that manifest itself? When we need help on something, we’re not starting from scratch.”

    That partnership has already borne fruit, with rapid expansion of warehouses in Hong Kong (where 12 have opened this year) and the planned establishment of the Dubai office, among other initiatives.

    Williamson also credits HKEX’s support with accelerating governance and cultural reform at the LME. “We’ve strengthened the LME board and management team. There’s much more ambition within the exchange as well as enhanced execution capabilities,” he said. “It’s been interesting to me to observe how the culture has changed. We’ve got a more proactive culture across the organization now.”

    Personal roots

    Despite the LME’s global scope, Williamson’s own story is deeply grounded in personal experience and people skills – something he traces back to his early years working in his father’s newsagent shop in Edinburgh, Scotland.

    “I worked there from the age of eight until I was 21,” he said. “I learned so much in that time about people – you learned to read people pretty quickly because our shop was on the border of the then less-attractive part of Edinburgh.”

    That grounding, he believes, shaped his approach to business and leadership. “Although I’m an accountant and I’ve been dealing with numbers all my life, I’m much happier dealing with people and people issues and people challenges,” he said.

    After earning a degree in accounting and computer science from Edinburgh’s Heriot-Watt University, he joined stockbroking firm Wood Mackenzie and started as a partnership tax assistant in Edinburgh. He gained the mentorship of a senior partner, who later encouraged him to move to London around the time of the so-called Big Bang in banking; they remain close friends some 42 years later.

    Williamson moved to Hong Kong in 1994 after Wood Mackenzie was acquired by UK bank NatWest, acting as the bank’s eyes and ears in a 50:50 investment bank joint venture with Wheelock, a major local conglomerate. His role focused on building the right team and establishing operations across the Asia region.

    In 1998, he then joined Morgan Stanley in Hong Kong to help expand its business in Asia, gaining valuable experience, not least in navigating the differences between US and UK banking cultures.

    In 2007, he was recruited by Robert Miller, co-founder of DFS Group, to be chief financial officer of Search Group, Miller’s private family office and asset management firm. Later, in 2012, Williamson was also appointed chief executive officer of SAIL Advisors, the group’s fund of hedge funds business.

    Meantime, in 2008, he had been approached to join the HKEX board. It proved an extraordinary time, with the global financial crisis unfolding and Hong Kong facing a series of challenges, from market turmoil to public health crises such as SARS and bird flu. Despite the turbulence, it was a fascinating period that saw HKEX begin to expand its international reach.

    Williamson was part of the board subcommittee that looked into acquiring the LME in 2012. “That was my first proper introduction to the world of metals,” he said.

    Looking ahead

    Reflecting on three years as chairman, Williamson said that his focus was still to ensure that the LME continues to evolve – cautiously, but decisively.

    “We’re very, very careful not to interfere with the structure of the LME’s core contracts,” he said. “But if we do not adapt to the changing requirements of the broader market, we’re in more danger of being left behind.”

    For all the challenges, he is optimistic and energized.

    “We’ve made remarkable progress over the past few years,” he said. “There’s no room for complacency, but I genuinely believe that the LME is poised to reach its full potential. We’re certainly heading in the right direction.”

    Want to hear more from about the London Metal Exchange? Listen to the exchange’s CEO, Matthew Chamberlain, in an episode of the Fast Forward podcast with Andrea Hotter below.

    Continue Reading

  • Strengthening ChatGPT’s responses in sensitive conversations – OpenAI

    1. Strengthening ChatGPT’s responses in sensitive conversations  OpenAI
    2. OpenAI prioritised user engagement over suicide prevention, lawsuit claims  Financial Times
    3. How ChatGPT Encourages Teens to Engage in Dangerous Behavior  Inside Higher Ed
    4. 10-21-25 open ai rolling out parental controls for ai chatbot chatgpt  radioplusinfo.com
    5. OpenAI Weakened ChatGPT’s Self-Harm Guardrails in Lead-Up to Teen’s Death, Lawsuit Says  Gizmodo

    Continue Reading

  • AI in Health Care and Biotechnology: Promise, Progress, and Challenges – Foley & Lardner LLP

    1. AI in Health Care and Biotechnology: Promise, Progress, and Challenges  Foley & Lardner LLP
    2. AI in Biotechnology Market to Reach $11.4 Billion by 2030  Yahoo Finance
    3. From wild fungi to faster drug discovery  Drug Target Review
    4. AI giants Nvidia, Microsoft and Google are making critical moves in pharma R&D  PharmaVoice
    5. Artificial Intelligence in Drug Discovery Market 2025-2032: Trends, Growth Drivers & Global Forecast  PharmiWeb.com

    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.mastercard.com/us/en/news-and-trends/press/2025/october/Mastercard-introduces-first-ever-threat-intelligence-solution.html” on this server.

    Reference #18.d9b31402.1761583326.6ad9acdc

    https://errors.edgesuite.net/18.d9b31402.1761583326.6ad9acdc

    Continue Reading